MedReleaf to Purchase 164 Acres with 23-Acre Greenhouse

Ontario-based cannabis producer MedReleaf Corp. (TSX:LEAF), today announced it has signed agreements to buy 1 million of (23 acres) of existing greenhouse on a 69-acre property in Exeter, Ontario, and 95 acres of adjacent land, for $21.5 million in cash and 225,083 common shares. The total deal is worth approximately CAD $26 million.

The stock rose 3% to CAD $14.93 on the news. The company has a market cap of CAD $1.37 billion, putting it easily among the top 10 largest cannabis producers globally by that measure. It reported revenue of $33 million in the past year, and has a price-to-sales ratio of 45. Like virtually all cannabis companies, it is still reporting negative income (-$3.5 million).

The Exeter facility, after retrofitting, will produce up to 105,000 kilograms of cannabis annually, with a first harvest expected by the end of 2018. Their currentproduction capacity is 12,600 kg, with expansion of their Bradford indoor facility—itself expected to produce 35,000 kilograms per year—underway and on track for completion by summer of 2018.

When fully operational, the new Exeter facility will increase their fully funded capacity to roughly 140,000 kilograms per year, putting Medreleaf among the top global producers.

The facility adds low-cost greenhouse production to their two higher-cost premium indoor production facilities in Markham and Bradford, Ontario. Adding this greenhouse will lower their unit production costs.

Greenhouses are ideal for growing cannabis used for extract production, complementing MedReleaf’s current indoor-grown cannabis.

The additional 95 acres of undeveloped land, if built out, could house a greenhouse 1.5 times larger even than the Exeter facility.

MedReleaf is fully funded to complete the retrofit of the Exeter Facility. The greenhouse will use environmental monitoring and control systems, supplemental lighting, irrigation systems, and automated growing systems

MedReleaf to Purchase 164 Acres with 23-Acre Greenhouse

Cannin Investment Group: Your Hemp Stocks Experts

Cannin.com is your trusted resource for hemp stocks. Our team of financial experts evaluates all emerging hemp stock investing opportunities. We aggregate hundreds of hours of market research to provide tips on the best hemp stocks for 2020.

Use Cannin as your resource for:

Is it too late to invest in hemp stocks? No! This is the perfect time to invest.

Wall Street analysts expect the global cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in hemp stocks is now.

Are you interested in hemp stocks like GW Pharmaceuticals, Charlotte’s Web, Canopy Growth, or Hemp Inc.?

Are you looking to buy stock in hemp companies or marijuana companies in 2020? Interested in emerging penny hemp stocks? Interested in leveraging the power of algorithmic stock trades to profit from hemp stocks? Looking for the best Canadian cannabis stocks to invest in? We can help.

Predict price movements of hemp stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
Backtested since 2012

At Cannin, we’re so confident you’ll love our algotrading hemp stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best hemp stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks

MedReleaf to Purchase 164 Acres with 23-Acre Greenhouse